IntelligeneCG LLC

Personnel

Director: Hana Albrecht, DO, ABPath, Lab Director
Phone: (913)258-3200
Fax: 843-628-3268
Email: intelligene@comtronusa.com

Conditions and tests

64 conditions/phenotypes with 11 tests
Enter text to narrow down the list

Breast adenocarcinoma1 test
Breast cancer, early-onset1 test
Breast cancer, familial male1 test
Breast cancer, susceptibility to1 test
Breast neoplasm1 test
Breast-ovarian cancer, familial, susceptibility to, 11 test
Breast-ovarian cancer, familial, susceptibility to, 21 test
Carcinoma of colon1 test
Carcinoma of pancreas1 test
Colorectal cancer, hereditary nonpolyposis, type 21 test
Colorectal cancer, susceptibility to, 11 test
Colorectal cancer, susceptibility to, 101 test
Colorectal cancer, susceptibility to, 111 test
Colorectal cancer, susceptibility to, 121 test
Colorectal cancer, susceptibility to, 21 test
Colorectal cancer, susceptibility to, 31 test
Colorectal cancer, susceptibility to, 41 test
Colorectal cancer, susceptibility to, 51 test
Colorectal cancer, susceptibility to, 61 test
Colorectal cancer, susceptibility to, 71 test
Colorectal cancer, susceptibility to, 81 test
Colorectal cancer, susceptibility to, 91 test
Endometrial carcinoma1 test
Endometrium neoplasm1 test
Familial cancer of breast1 test
Familial colorectal cancer1 test
Familial medullary thyroid carcinoma1 test
Familial melanoma1 test
Familial pancreatic carcinoma1 test
Familial prostate carcinoma1 test
Hereditary breast ovarian cancer syndrome1 test
Li-Fraumeni syndrome1 test
Li-Fraumeni syndrome 11 test
Li-Fraumeni syndrome 21 test
Li-fraumeni-like syndrome1 test
Lynch syndrome1 test
Lynch syndrome 11 test
Malignant melanoma of skin1 test
Malignant tumor of prostate1 test
Melanoma1 test
Melanoma, cutaneous malignant, susceptibility to, 11 test
Melanoma, cutaneous malignant, susceptibility to, 21 test
Melanoma, cutaneous malignant, susceptibility to, 31 test
Melanoma, cutaneous malignant, susceptibility to, 41 test
Melanoma, cutaneous malignant, susceptibility to, 51 test
Melanoma, cutaneous malignant, susceptibility to, 61 test
Melanoma, cutaneous malignant, susceptibility to, 71 test
Melanoma, cutaneous malignant, susceptibility to, 81 test
Melanoma, cutaneous malignant, susceptibility to, 91 test
Multiple endocrine neoplasia1 test
Multiple endocrine neoplasia type 41 test
Multiple endocrine neoplasia, type 11 test
Multiple endocrine neoplasia, type 21 test
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA1 test
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB1 test
Neoplasm of stomach1 test
Neoplasm of the genitourinary tract1 test
Neoplasm of uterine cervix1 test
Neoplasm of uterus1 test
Papillary renal cell carcinoma type 11 test
Prostate cancer, hereditary, 11 test
Stomach cancer, familial1 test
Tumor predisposition syndrome 31 test
Urinary bladder carcinoma1 test

List of services

Clinical Testing/Confirmation of Mutations Identified Previously
Custom Sequence Analysis
Carrier testing
DNA Banking
Genetic counseling
Insurance appeals support
Insurance billing
Insurance preauthorization
Insurance preverification
Mutation Confirmation
Result interpretation
Whole Exome Sequencing
Whole Genome Sequencing

List of certifications/licenses

Certifications

CLIAHelpCertification number assigned by the Clinical Laboratory Improvement Amendments (CLIA) program to the laboratory director. Minimal field for US labs offering clinical tests. Optional field for international labs or US labs performing research tests. If pending renewal or record has not been updated, the expiration date may be in the past., Number: 17D2097343, Expiration date: 2023-01-12

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.